What is Affymax?
Affymax, Inc., founded in 2001 and based in New York, was previously engaged in the development of drugs aimed at improving the treatment of serious and life-threatening conditions in the United States. However, the company currently does not appear to have significant ongoing operations.
How much funding has Affymax raised?
Affymax has raised a total of $92.5M across 1 funding round:
Stock Offering
$92.5M
Stock Issuance/Offering (2006): $92.5M, investors not publicly disclosed
What's next for Affymax?
The substantial enterprise-level funding, including the recent major strategic investment, suggests a pivotal moment for Affymax. While the company's operational status is noted as limited, this capital infusion could signal a strategic pivot, a restructuring effort, or the initiation of new development pathways. Further analysis of the investment's specific terms and the strategic objectives of the backers would be crucial to understanding Affymax's future trajectory and potential for renewed growth.
See full Affymax company page
